Last reviewed · How we verify
Letrozole 2.5mg, hCG
Letrozole 2.5mg, marketed by Rigshospitalet in Denmark, is an established drug with a key composition patent expiring in 2028. Its primary strength lies in its well-established market presence and long-term use. The primary risk is the potential increase in generic competition following the patent expiry in 2028.
At a glance
| Generic name | Letrozole 2.5mg, hCG |
|---|---|
| Sponsor | Rigshospitalet, Denmark |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Endometrial Preparation in Frozen Embryo Transfer Cycles (PHASE4)
- A Randomized, Double-blinded, Clinical, Placebo-controlled Trial on the Effects of Therapy With Letrozole and hUman Choriongonadotropin in Male Hypogonadism Induced by Illicit Use of Anabolic Androgenic Steroids- The LUCAS Trial (PHASE4)
- Clinical Observation of Warm Needling Combined With and Electroacupuncture Therapy on Ovulatory Dysfunction (NA)
- Different Induction Protocols in PCOS After Clomiphene Citrate Failed Pregnancy in Non-IVF Cycles (PHASE4)
- Minimal Stimulation Protocol Using Aromek(Letrozole) and Follitrope(recFSH) Combined With INVOCell-Low Cost IVF
- Does Letrozole Improve Pregnancy Outcome in Fresh Embryo Transfer IVF/ICSI Cycle? (PHASE4)
- Endometrial Preparation in Frozen Embryo Transfer Cycles (NA)
- Role of Aromatase Inhibitor to Enhance Ovulation in Poor Responder During Induction With Short Antagonist Protocol in Cases of ICSI (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Letrozole 2.5mg, hCG CI brief — competitive landscape report
- Letrozole 2.5mg, hCG updates RSS · CI watch RSS
- Rigshospitalet, Denmark portfolio CI